Avalyn Pharma Inc. Common Stock
AVLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$1.21
96.7% downside
Current Fair Value
96.7% downsideOvervalued by 96.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.43 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.04 |
| Beta | -1.13 |
| Outstanding Shares | 41,812,047 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -16.63 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | -5.23 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.78
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 2, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Avalyn Pharma Inc. Common Stock
50 employees
CEO: Lyn Baranowski Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis ...